We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Test Specifically Detects Mobile Colistin Resistance in Isolates

By LabMedica International staff writers
Posted on 22 Feb 2017
Scientists have evaluated a commercially available LAMP-based assay for rapid detection of the plasmid-encoded mobile colistin resistance gene mcr-1 in Enterobacteriaceae isolates. More...
With further development and evaluation, it can likely also be used in hospitals and for livestock.

Scientists from the German Center for Infection Research (DZIF) and the Justus Liebig University (JLU) Giessen (also Giessen University) evaluated the test, which detects the mcr-1 within 20 minutes.

Colistin is used as a “last-resort antibiotic” for multidrug-resistant pathogens, especially in hospitals. However, some gut bacteria have become insensitive to colistin due to the mobile colistin resistance gene mcr-1. In early 2016, bacteria carrying mcr-1 were detected in Germany for the first time and there is growing concern that it may develop into a superbug against which even emergency antibiotics are no longer effective. Risk of further spread of this colisitin resistance is high because it takes place through plasmids, which are transferred between different types of bacteria relatively easily.

“Confirming the mobile mcr-1 resistance gene as rapidly as possible is important so as to prevent its further spread,” emphasized Linda Falgenhauer, DZIF scientist at Giessen University and a co-first-author of this study. She, with colleagues from Giessen University and from the research association RESET, tested a rapid genotypic resistance test for colistin that is already commercially available. “This is the only way with which mobile resistance can be differentiated from common resistance, because phenotypically they are the same,” said co-first-author Can Imirzalioglu, DZIF scientist at Giessen University.

For the evaluation of this test, AmplexBiosystems GmbH provided the testing kits free of charge. The scientists tested 104 bacterial isolates from animals, humans, and the environment: the results were compared to those from complete genome sequencing or PCR, and demonstrated 100% sensitivity and specificity. So the test could clearly differentiate between common colistin resistance and mobile resistance located on plasmids. However, applying the test directly to clinical samples has not yet been evaluated, it only been applied to bacterial cultures.

“The test results become available in only twenty minutes,” said co-author Judith Schmiedel, from the Giessen team, “With the conventional procedure, it takes several hours to get results. Additionally, the system is very uncomplicated, so it should be developed further for future use in hospitals as well as for livestock farming and food production.” With an “interdisciplinary collaboration, we are following the One Health approach which takes into account the systemic connections between humans, animals, the environment, and health in order to fight antibiotic resistance,” said Prof. Trinad Chakraborty, of JLU Giessen and coordinator of the DZIF partner-site Giessen-Marburg-Langen.

The study, by Imirzalioglu C et al, was published online ahead of print January 30, 2017, in the journal Antimicrobial Agents and Chemotherapy.


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Creatine Kinase-MB Assay
CK-MB Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.